TY - JOUR
T1 - Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease
AU - Hammes, Luciano S.
AU - Tekmal, Rajeshwar Rao
AU - Naud, Paulo
AU - Edelweiss, Maria Isabel
AU - Kirma, Nameer
AU - Valente, Philip T.
AU - Syrjänen, Kari J.
AU - Cunha-Filho, João Sabino
N1 - Funding Information:
This work was supported by grant 0629/05-7 from the Foundation for the Coordination of Higher Education and Graduate Training (CAPES), Brazil, by grant 05-154 from Hospital de Clínicas de Porto Alegre Research Incentive Fund (HCPA-FIPE), Brazil, by Latin American Screening study, funded by European Commission, INCO-DEV Contract # ICA4-CT-2001-10013, and by NIH/NCI grant P30 CA54174 (RRT). We thank Mr. Gregory A. Langone, Ms. Joanne Click and Ms. Renata Pedrini for the technical assistance. We are also grateful to Prof. Nadine Clausell Ph.D. and Ms. Indara Carmin for the unique support for this project.
PY - 2008/9
Y1 - 2008/9
N2 - Objectives: To describe the expression of vascular endothelial growth factor (VEGF), proto-oncogene macrophage colony-stimulating factor receptor (c-fms) and cyclooxygenase-2 (COX-2) in cervical carcinogenesis and to analyze the correlation of VEGF with c-fms and COX-2 expression. Methods: In this study, 26 cases of benign cervix, 28 low-grade cervical intraepithelial neoplasia (CIN; CIN 1), 30 high-grade CIN (CIN 2/3) and 28 squamous cervical carcinomas (SCC) were examined by immunohistochemistry (IHC) and analysis was performed separately for epithelium and stroma. Results: Positive epithelial expressions in normal cervix, low-grade CIN, high-grade CIN and SCC were, respectively: VEGF - 11.5%, 39.3%, 53.3% and 75% (P < 0.001); c-fms - 0%, 10.7%, 40% and 67.9% (P < 0.001); COX-2 - 7.7%, 39.3%, 80% and 100% (P < 0.001). Stromal VEGF expression was higher than epithelial expression in all CIN grades and was also associated with the lesion grade, while c-fms and COX-2 stromal expression was weak. VEGF expression was statistically correlated to c-fms and COX-2 expression in high-grade CIN (P = 0.020 and P = 0.027, respectively) and SCC (P = 0.015 and P = 0.005, respectively). Conclusions: On the basis of our findings, these factors may participate in the development and progression of CIN lesions, with possible interaction of c-fms and COX-2 on VEGF expression, and may be potential molecular targets for studies of cervical cancer prevention and treatment.
AB - Objectives: To describe the expression of vascular endothelial growth factor (VEGF), proto-oncogene macrophage colony-stimulating factor receptor (c-fms) and cyclooxygenase-2 (COX-2) in cervical carcinogenesis and to analyze the correlation of VEGF with c-fms and COX-2 expression. Methods: In this study, 26 cases of benign cervix, 28 low-grade cervical intraepithelial neoplasia (CIN; CIN 1), 30 high-grade CIN (CIN 2/3) and 28 squamous cervical carcinomas (SCC) were examined by immunohistochemistry (IHC) and analysis was performed separately for epithelium and stroma. Results: Positive epithelial expressions in normal cervix, low-grade CIN, high-grade CIN and SCC were, respectively: VEGF - 11.5%, 39.3%, 53.3% and 75% (P < 0.001); c-fms - 0%, 10.7%, 40% and 67.9% (P < 0.001); COX-2 - 7.7%, 39.3%, 80% and 100% (P < 0.001). Stromal VEGF expression was higher than epithelial expression in all CIN grades and was also associated with the lesion grade, while c-fms and COX-2 stromal expression was weak. VEGF expression was statistically correlated to c-fms and COX-2 expression in high-grade CIN (P = 0.020 and P = 0.027, respectively) and SCC (P = 0.015 and P = 0.005, respectively). Conclusions: On the basis of our findings, these factors may participate in the development and progression of CIN lesions, with possible interaction of c-fms and COX-2 on VEGF expression, and may be potential molecular targets for studies of cervical cancer prevention and treatment.
KW - Angiogenesis
KW - Cervical cancer
KW - Cervical intraepithelial neoplasia
KW - Cyclooxygenase-2
KW - Macrophage colony-stimulating factor receptor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=50149101717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50149101717&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2008.04.038
DO - 10.1016/j.ygyno.2008.04.038
M3 - Article
C2 - 18565574
AN - SCOPUS:50149101717
SN - 0090-8258
VL - 110
SP - 445
EP - 451
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -